Fremont, Calif.-based proteomics diagnostics firm Vermillion announced this week that the European Patent Office has issued a decision to grant it a patent covering its use of biomarkers for the detection of ovarian cancer.
The patent, entitled "Use of Biomarkers for Detecting Ovarian Cancer," marks a significant step in the company's efforts to commercialize its OVA1 ovarian cancer protein biomarker test.
"The granting of this patent in Europe will help support our efforts to expand our commercialization into the EU," Vermillion CEO and executive chairperson Gail Page said in a statement. "We are actively engaged in the processes required to offer OVA1 in the EU."
The company, which emerged from Chapter 11 bankruptcy protection in January, received FDA approval for the OVA1 test in September 2009 and began selling the test in the US in March.